ArticleScientific reports2023
A smartphone- and wearable-based biomarker for the estimation of unipolar depression severity.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Digital Biomarkers in Physiological Signal-Based Depression Assessment: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Individual-Level Modeling of Depressive Symptom Severity Using Smartphone and Wearable Data: Time-Aware 1-Year Study With Feature-Group Contributions.JMIR formative research · 2026Article
- Contribution of Longitudinal Mobile Health Measures in the Dynamic Track of Patients With Major Depressive Disorder: Multiple Centers, Prospective Cohort Study Using Functional Data Analysis and Machine Learning.JMIR mHealth and uHealth · 2026Article
- Clinical and Behavioral Outcomes During 4 Weeks of Home-Based Self-Administered Transcranial Direct Current Stimulation in Perinatal Women With Depressive Symptoms: Open-Label Exploratory Pilot Study.JMIR formative research · 2026Article
- Sensor-Equipped Digital Technologies for Monitoring and Detecting Depressive Disorders: A Systematic Review.Health science reports · 2026Review
- Digital Biomarkers in Depression: Integrating DSM-5-TR Symptomatology and RDoC Psychological Systems.Current psychiatry reports · 2026Review
- Prospective observational study on behavioral monitoring, disease progression assessment, and screening model development for patients with depression using wearable devices and mobile phones: protocol.Frontiers in psychiatry · 2026Article
- Effects of Smartphone-Based Hospital-Family Transitional Care on Symptom Burden and Quality of Life in Elderly Patients with Depression.Alpha psychiatry · 2025Article
- Developing interactive VR-based digital therapeutics for Acceptance and Commitment Therapy (ACT): a structured framework for the digital transformation integrating gamification and multimodal arts.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug development for mood disorders can greatly benefit from the development of robust, reliable, and objective biomarkers. The incorporation of smartphones and wearable devices in clinical trials provide a unique opportunity to monitor behavior in a non-invasive manner. The objective of this study is to identify the correlations between remotely monitored self-reported assessments and objectively measured activities with depression severity assessments often applied in clinical trials. 30 unipolar depressed patients and 29 age- and gender-matched healthy controls were enrolled in this study. Each participant's daily physiological, physical, and social activity were monitored using a smartphone-based application (CHDR MORE™) for 3 weeks continuously. Self-reported depression anxiety stress scale-21 (DASS-21) and positive and negative affect schedule (PANAS) were administered via smartphone weekly and daily respectively. The structured interview guide for the Hamilton depression scale and inventory of depressive symptomatology-clinical rated (SIGHD-IDSC) was administered in-clinic weekly. Nested cross-validated linear mixed-effects models were used to identify the correlation between the CHDR MORE™ features with the weekly in-clinic SIGHD-IDSC scores. The SIGHD-IDSC regression model demonstrated an explained variance (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.